InnoCare Pharma (HKSE:09969) FCF Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InnoCare Pharma's Free Cash Flow for the three months ended in Sep. 2023 was HK$0.0 Mil. InnoCare Pharma's Revenue for the three months ended in Sep. 2023 was HK$171.4 Mil. Therefore, InnoCare Pharma's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, InnoCare Pharma's current FCF Yield % is 0.00%.

The historical rank and industry rank for InnoCare Pharma's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of InnoCare Pharma was -0.40%. The lowest was -49723.14%. And the median was -7371.99%.

HKSE:09969's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.24
* Ranked among companies with meaningful FCF Margin % only.

InnoCare Pharma FCF Margin % Historical Data

The historical data trend for InnoCare Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma FCF Margin % Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-12,409.08

-31,067.97

-0.40

-149.64

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of InnoCare Pharma's FCF Margin %

For the Biotechnology subindustry, InnoCare Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's FCF Margin % falls into.

InnoCare Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

InnoCare Pharma's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-1045.112	/	698.398
	=	-149.64 %

InnoCare Pharma's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0	/	171.432
	=	0.00 %

InnoCare Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines